Product
Nal-IRI
1 clinical trial
2 indications
Indication
Esophageal adenocarcinomaIndication
Stomach AdenocarcinomaClinical trial
Phase 2 Trial of 5-Fluorouracil, Oxaliplatin and Liposomal Irinotecan and Immunotherapy (Plus Trastuzumab for HER2-positive Disease) During 1st Line Treatment of Advanced Esophageal and Gastric AdenocarcinomaStatus: Recruiting, Estimated PCD: 2025-12-01